2. Academic Validation
  3. 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibition: A Potential Treatment Option for Non-Small Cell Lung Cancer

17β-Hydroxysteroid Dehydrogenase Type 1 Inhibition: A Potential Treatment Option for Non-Small Cell Lung Cancer

  • ACS Med Chem Lett. 2021 Nov 18;12(12):1920-1924. doi: 10.1021/acsmedchemlett.1c00462.
Emanuele M Gargano 1,  Abdelrahman Mohamed 1 2,  Ahmed S Abdelsamie 3 4,  Giuseppe F Mangiatordi 5,  Hanna Drzewiecka 6,  Paweł P Jagodziński 6,  Arcangela Mazzini 1,  Chris J van Koppen 7,  Matthias W Laschke 8,  Orazio Nicolotti 5,  Angelo Carotti 5,  Sandrine Marchais-Oberwinkler 1,  Rolf W Hartmann 1 3,  Martin Frotscher 1
Affiliations

Affiliations

  • 1 Department of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C23, D-66123 Saarbrücken, Germany.
  • 2 Pharmaceutical Organic Chemistry Department, Assiut University, Assiut 71526, Egypt.
  • 3 Department of Drug Design and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Campus E81, D-66123 Saarbrücken, Germany.
  • 4 Chemistry of Natural and Microbial Products Department, National Research Centre, Dokki, Cairo 12311, Egypt.
  • 5 Dipartimento di Farmacia Scienze del Farmaco, Università degli Studi di Bari, V. Orabona 4, I-70125 Bari, Italy.
  • 6 Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Świȩcickiego 6 Street, 60-781 Poznan, Poland.
  • 7 ElexoPharm GmbH, Campus A12, D-66123 Saarbrücken, Germany.
  • 8 Institute for Clinical and Experimental Surgery, Saarland University, D-66421, Homburg, Saar, Germany.
PMID: 34917255 DOI: 10.1021/acsmedchemlett.1c00462
Abstract

In the face of the clinical challenge posed by non-small cell lung Cancer (NSCLC), the present need for new therapeutic approaches is genuine. Up to now, no proof existed that 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) is a viable target for treating this disease. Synthesis of a rationally designed library of 2,5-disubstituted furan derivatives followed by biological screening led to the discovery of 17β-HSD1 inhibitor 1, capable of fully inhibiting human NSCLC Calu-1 cell proliferation. Its pharmacological profile renders it eligible for further in vivo studies. The very high selectivity of 1 over 17β-HSD2 was investigated, revealing a rational approach for the design of selective inhibitors. 17β-HSD1 and 1 hold promise in fighting NSCLC.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z